Athersys gets FDA approval to study MultiStem therapy for Covid-19

MACOVIA’s primary objectives are the safety and efficacy of MultiStem therapy in patients with moderate to severe ARDS caused by Covid-19. Credit: Fusion Medical Animation on Unsplash.



  • Athersys